Imatinib mesylate associated with delayed hematopoietic recovery after concomitant chemotherapy.
D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use; D001549:Benzamides; D006410:Hematopoiesis / Q000187:drug effects*; D006801:Humans; D000068877:Imatinib Mesylate; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy / Q000628:therapy; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000628:therapy; D008224:Lymphoma, Follicular; D008297:Male; D016609:Neoplasms, Second Primary / Q000188:drug therapy / Q000628:therapy; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate